



NDA 206162/S-007

**SUPPLEMENT APPROVAL  
FULFILLMENT OF POSTMARKETING REQUIREMENT  
RELEASE FROM POSTMARKETING REQUIREMENT**

AstraZeneca Pharmaceuticals LP  
Attention: Karen McCullough, PhD  
Director, Global Regulatory Affairs Oncology  
One MedImmune Way  
Gaithersburg, MD 20878

Dear Dr. McCullough:

Please refer to your Supplemental New Drug Application (sNDA) dated May 17, 2017, received May 17, 2017, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lynparza<sup>®</sup> (olaparib), oral capsules.

This Prior Approval supplemental new drug application provides for updates to the Prescribing Information based on the post-marketing signal of hypersensitivity characterized by rash and dermatitis. In addition, this supplement provides, via cross-reference to NDA 208558 for Lynparza<sup>®</sup> (olaparib) tablets, the final clinical study report for PMR 2824-1 from the December 19, 2014, approval letter for this NDA. Notifications were added to the Prescribing Information regarding the differences in the dosing and bioavailability of the capsule and tablet formulations.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert and Medication Guide), with the addition of any labeling changes in pending "Changes Being Effectuated" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories. Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **SUBPART H FULFILLED**

We approved this NDA under the regulations at 21 CFR 314 Subpart H for accelerated approval of new drugs for serious or life-threatening illnesses. Approval of this supplement fulfills your commitment made under 21 CFR 314.510 for the following postmarketing requirement:

2824-1      Submit the progression-free survival (PFS) and overall survival (OS) analyses with datasets from clinical trial D0818C00002, SOLO-2, the ongoing randomized double-blind, placebo-controlled, multi-center trial to assess the efficacy of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSO) patients (including patients with primary peritoneal and/or fallopian tube cancer) or high grade endometrioid cancer with BRCA mutations (documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)) who have responded following platinum-based chemotherapy.

Interim Report (PFS analysis)	02/2016
Trial Completion Date	12/2018
Final Report Submission (OS analysis)	03/2019

### **RELEASE FROM POSTMARKETING REQUIREMENT**

We have received your submission dated August 14, 2017, providing authorization to cross-reference NDA 208558 for the final clinical study report for PMR 2824-1 listed in our December 19, 2014, approval letter:

2824-2      Submit the progression-free survival (PFS) and overall survival (OS) analyses with datasets from clinical trial D0816C00010, a randomized trial establishing the superiority of olaparib over physician’s choice single-agent chemotherapy in the treatment of platinum sensitive relapsed ovarian cancer in patients carrying deleterious or suspected deleterious germline BRCA1/2 mutations.

The original timetable you submitted on November 13, 2014, states that you will conduct this trial according to the following schedule:

Interim report:	06/2018
Trial Completion Date:	03/2020
Final Report Submission:	06/2020

We have reviewed your submission and have determined that you are released from the above postmarketing requirement for the following reasons:

Interim progression-free survival data from SOLO-2 have verified the clinical benefit of olaparib and therefore olaparib capsules for monotherapy in patients with deleterious or suspected deleterious germline *BRCA*-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy is granted regular approval. Therefore, PMR 2824-2 is no longer needed.

We remind you that there are postmarketing requirements listed in the December 19, 2014, approval letter that are still open.

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

OPDP Regulatory Project Manager  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion (OPDP)  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at:

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf> ).

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>.

Information and Instructions for completing the form can be found at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For

more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Rajesh Venugopal, Senior Regulatory Project Manager, at (301) 796-4730.

Sincerely,

*{See appended electronic signature page}*

Julia Beaver, MD  
Acting Director  
Division of Oncology Products 1  
Office of Hematology and Oncology Products  
Center for Drug Evaluation and Research

ENCLOSURE:

Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

JULIA A BEAVER  
08/17/2017